Astonea Labs IPO opens today; check price band, lot size, GMP, key dates

Astonea Labs IPO: The initial public offering (IPO) of Astonea Labs opens for public subscription today, May 27, 2025. Valued at around ₹37.67 crore, the SME offering comprises an entirely fresh issue of 2.79 million equity shares. As the public offering opens for subscription, Here are the key details of the Astonea Labs IPO as outlined in its Red Herring Prospectus:
Astonea Labs IPO price band, lot size
Astonea Labs IPO will be available at a price band of ₹128-135 per share, with a lot size of 1,000 shares. A retail investor can bid for a minimum of one lot of 1,000 shares, with an investment amount of ₹1,35,000 (at the upper end of the IPO price). A high net-worth individual (HNI) would require a minimum of ₹2,70,000 to bid for a minimum of two lots of 2,000 equity shares.
Astonea Labs IPO grey market premium (GMP)
Astonea Labs IPO allotment date, listing date
The public offering of Astonea Labs will remain available for subscription until Thursday, May 29, 2025. Following the closure of the subscription window, the basis of allotment of Astonea Labs IPO shares is likely to be finalized on Friday, May 30, 2025. The successful allottees can expect the company's shares to be credited to their demat accounts by Monday, June 2, 2025.
Shares of Astonea Labs are slated to list on the BSE SME on Tuesday, June 3, 2025.
Astonea Labs registrar, lead manager
Kfin Technologies serves as the registrar for the public offering of Astonea Labs, while Oneview Corporate Advisors serves as the sole book-running lead manager. ALSO READ | Unified Data-Tech IPO allotment today; check status, GMP, listing date
Astonea Labs IPO objective
Astonea Labs intends to utilise the net proceeds from the public offering for funding expenses proposed to be incurred towards product registration in Bolivia, South America; for the purchase and installation of plant and machinery for ointment production for export purposes in accordance with international standards and protocols, on the 2nd floor of the Existing Premises (factory at Haripur, Tehsil - Raipur Rani, District Panchkula, Haryana, referred to as the 'Existing Premises'). The company will further use the proceeds for advertising, marketing and brand building, investment in procuring hardware and software, funding working capital requirements, and for general corporate purposes.
About Astonea Labs
Astonea Labs specialises in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products. These include antibiotic drugs, anti-cold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynecological concerns, analgesics, fungal infections, and multivitamins. The company also offers products for skin, tooth, and hair care, available in various forms such as gels, ointments, creams, lotions, oils, and serums. Additionally, Astonea Labs is involved in the trading of certain packaging materials and raw materials used in pharmaceutical and cosmetic products.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

News18

11 hours ago

• News18

Influx Healthtech IPO Receives Over 201.3x Subscription On Final Day Of Bidding; Check GMP Today

The GMP of the Influx Healthtech IPO is 18.75%, indicating strong listing gains for investors. Influx Healthtech IPO Day 3: The initial public offering of Influx Healthtech Ltd has been closed today, Friday, June 20. The IPO has received a strong response from investors. Till 5:00 pm on the final day of bidding on Friday, the Rs 55.63-crore SME IPO received an overwhelming 201.35 times subscription, garnering bids for 81,71,71,200 shares as against 40,58,400 shares on offer. The retail and NII participation stood at 117.68 times and 481.10 times, respectively. Its qualified institutional buyer (QIB) category got a 137.87 times subscription. The three-day IPO was opened on Wednesday, June 18. It received a 5.89 times subscription on Day 1 on Wednesday and a 25.47 times subscription on Day 2. Influx Healthtech IPO Price The price of the Influx Healthtech IPO has been fixed at Rs 96 apiece. Influx Healthtech IPO Lot Size The minimum lot size is 1,200 shares, requiring a retail investment of Rs 1,15,200. For NIIs, the minimum is 2 lots (2,400 shares) at Rs 2,30,400. According to market observers, the GMP of the Influx Healthtech IPO is 18.75%, indicating strong listing gains for investors. The 18.75% GMP is significantly lower than the 39.58% premium recording in the morning. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. The shares of Influx Healthtech Ltd will be listed on the NSE SME on June 25. The Eppeltone Engineers IPO is a book-built issue worth Rs 55.63 crore, comprising a fresh issue of 46.94 lakh equity shares worth Rs 45.07 crore and an offer for sale of 11 lakh shares aggregating to Rs 10.56 crore. The IPO opened for subscription on June 18, 2025, and will close on June 20, 2025. Share allotment is likely to be finalised on June 23, with the listing expected on the NSE SME platform on June 25, 2025. The price band is set at Rs 96 per share. Influx Healthtech Ltd's revenue increased 5% and its profit after tax (PAT) rose 19% between the financial year ending with March 31, 2025, and March 31, 2024. Rarever Financial Advisors Pvt Ltd is the book-running lead manager of the Influx Healthtech IPO, while Maashitla Securities Private Limited is the registrar for the issue. The market maker for Influx Healthtech IPO is R K Stock Holding Private Limited. Influx Healthtech Ltd, founded in September 2020, is a healthcare-focused CDMO with three manufacturing units in Thane, producing tablets, capsules, powders, liquid orals, and softgels.

Hans India

13 hours ago

• Hans India

HDB Financial IPO leaves early investors facing big losses

New Delhi: The upcoming IPO of HDB Financial Services, worth Rs 12,500 crore, is turning out to be a worrying event for many early investors. According to the latest Red Herring Prospectus (RHP) filed on June 19, over 49,000 individual shareholders may suffer notional losses of up to 48 per cent. As of June 19, the company had 49,553 individual shareholders. These investors had bought HDB shares in earlier private transactions at prices ranging from Rs 1,200 to Rs 1,350 per share. But now, with the IPO priced at Rs 700 to Rs 740 per share, these shareholders are seeing the value of their investments drop sharply -- by 38 to 48 per cent, depending on the price at which they originally bought the shares. For instance, an investor who purchased 1 crore shares at Rs 1,250 each would have invested Rs 1,250 crore. At the current IPO price of Rs 740, the value of those shares would fall to Rs 740 crore, leading to a notional loss of Rs 510 crore. The IPO pricing is also lower than what was suggested by the grey market -- an unofficial market where shares are traded before they are listed on stock exchanges. HDB's public issue includes a fresh issue of Rs 2,500 crore and an offer-for-sale (OFS) worth Rs 10,000 crore by its parent company, HDFC Bank. As part of the OFS, HDFC Bank is selling 13.51 crore shares. Interestingly, HDFC Bank had acquired its stake in HDB at an average cost of just Rs 46.4 per share. So, even at Rs 740 per share, the bank is likely to make a massive profit of Rs 9,373 crore from this sale, before taxes. Meanwhile, at the upper end of the price band, the company is aiming for a post-money valuation of approximately $7.2 billion, or around Rs 62,000 crore.

Economic Times

16 hours ago

• Economic Times

BSE introduces AI tool to speed up SME IPO document checks

Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel BSE has launched a new generative AI tool to help speed up the initial checking process of SME IPO documents. Right now, vetting these documents can take several days or even weeks — but with this new tool, experts say the process could be reduced to just 30–40 per a recent circular, merchant bankers — who handle IPO filings — will be given access to a special folder where they can upload draft IPO documents. The AI tool will scan the draft and highlight any sections that need improvement or corrections before final submission."This tool is meant to improve the SME listing experience," said BSE. The AI tool will be accessed through a secure file transfer system (SFTP) and will serve as a pre-check mechanism, helping bankers make the draft more compliant before officially filing it with the its inception, the BSE SME platform has listed around 600 companies and helped raise nearly Rs 9,500 crore. The combined market value of these listed SMEs is over Rs 68,500 you include companies that have shifted from SME to the main board, the total jumps to about Rs 1.73 lakh crore. Around 200 firms have made that move so Joshi, founder of MMJC and Associates, called the move a 'progressive shift.' He said that while document vetting usually took a week, this AI tool could do it in under an hour. However, this facility is just for initial advice. The BSE will still review the final filing in full before giving official read: Sebi proposes 5-point AI rulebook for securities market. Check details This AI tool won't replace BSE's review, but it will help merchant bankers catch and fix issues earlier — making the IPO filing process smoother and faster.